CoPARC: Colorado Pulmonary Alcohol Research Collaborative

CoPARC：科罗拉多州肺酒精研究合作组织

• 批准号: 9926794
• 负责人: ELLEN L BURNHAM
• 金额: $ 70.15万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9926794
• 关键词: Acetaldehyde; Acetylcarnitine; Admission activity; Adult Respiratory Distress Syndrome; Alcohol consumption; Alcohols; Aliquot; Alveolar Macrophages; Area; Biocompatible Materials; Blood; Blood specimen; Bronchoalveolar Lavage Fluid; Bronchoscopy; Burn injury; California; Cannabis; Cells; Chicago; Clinical; Collection; Colorado; Communication; Communities; Critical Illness; Data; Data Set; Development; Economic Burden; Emerging Technologies; Endotoxins; Enrollment; Ensure; Epithelial Cells; Equipment and supply inventories; Erythrocytes; Evaluation; Exhalation; Faculty; Fatty Acids; Fostering; Funding; Generations; Genomics; Geography; Goals; Grant; Growth; Health; Histologic; Host Defense; Host Defense Mechanism; Human; Immune system; Immunity; Immunoglobulins; Inflammatory; Infrastructure; Institution; Intensive Care Units; Knowledge; Lipids; Louisiana; Lung; Lung diseases; Malondialdehyde; Marketing; Mechanical ventilation; Medical center; Mission; Monoclonal Antibody R24; Morbidity - disease rate; Nasal Epithelium; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; Nebraska; Needs Assessment; Online Systems; Oropharyngeal; Outcome; Oxidative Stress; Pathology; Patient-Focused Outcomes; Patients; Peripheral Blood Mononuclear Cell; Phospholipids; Plasma; Pneumonia; Production; Proteins; Publications; Recording of previous events; Research; Research Personnel; Research Subjects; Resources; Respiratory Failure; Respiratory System; Risk; Risk Factors; San Francisco; Site; Smoker; Specimen; Strategic Planning; Streptococcus pneumoniae; System; Targeted Research; Taxonomy; Therapeutic Intervention; Time; Tissues; Translational Research; Universities; Urine; adduct; airway epithelium; alcohol effect; alcohol research; alcohol use disorder; antimicrobial peptide; base; biomarker development; burden of illness; career development; clinical material; cytokine; data sharing; genome sequencing; improved; innovation; lung microbiome; marijuana use; microbiome alteration; microbiota; mortality; novel; pathogen; prevent; prophylactic; racial diversity; receptor expression; response; whole genome

Project Summary The goal of this proposal is to seek continued support to augment and sustain an established Alcohol Research Resource, known as CoPARC (Colorado Pulmonary-Alcohol Research Collaborative). CoPARC's mission is to facilitate research that will prevent the development of alcohol-associated pneumonia, ameliorate its deleterious complications, and ultimately improve clinical outcomes. Alcohol use disorders (AUDs) confer an eight-fold increased risk for community-acquired pneumonia. AUDs also increase morbidity for patients with pneumonia, including increasing the risk of respiratory failure necessitating intensive care unit (ICU) admission and mechanical ventilation. Further, AUD-associated pneumonia is frequently complicated by the development of the acute respiratory distress syndrome (ARDS). Centered at the University of Colorado Denver (UCD) and led by Ellen L. Burnham, MD, MS, the CoPARC infrastructure has enabled enrollment of over 370 ambulatory subjects with and without AUDs, and 237 critically ill patients with pneumonia or burn injury, established ARDS risk factors that are more prevalent in patients with AUDs. Resource materials have originated from institutions with a history of NIAAA-funded translational research in alcohol-related pulmonary diseases, including UCD, Emory University (EU), and Loyola University Chicago (LUC); and from the University of California San Francisco (UCSF) with NHLBI support. Presently, thousands of biospecimens have been collected, including bronchoalveolar lavage (BAL) fluid and cell aliquots; bronchial brushings; and blood specimens. To date, 26 investigators from 11 external institutions have utilized over 6100 biospecimens from 92% of the enrolled subjects. For the renewal, 4 sites (EU, LUC, UCSF, and the University of Nebraska Medical Center) and UCD will collect materials for CoPARC. A Steering Committee comprised of investigators from UCD, EU, LUC, Louisiana State University, UNMC, and Thomas Jefferson University will provide rigorous oversight for CoPARC, including prioritization of biospecimen distribution, and ensuring that milestones promoting use of the Resource are achieved. Innovations that are planned include collection of novel specimens such as whole lung explants; expertise in high-throughput genomics applications; access to administrative data sets enriched in patients with alcohol use; and organization of clinical, inventory, and experimental data to foster cross- investigator sharing. Aims for the renewal are in line with the NIAAA's strategic plan to identify mechanisms of alcohol action and alcohol-related pathology to more fully understand how alcohol asserts its effects on human health. They include: 1) expand and diversify clinical and biological materials obtained from ambulatory subjects with AUDs and critically ill patients, along with appropriate controls, 2) engage emerging web-based systems to prioritize data and biospecimen sharing, and streamline communications between investigators as well as the Steering Committee and 3) enhance visibility and marketing to promote the distribution, growth, and sustainability of the Resource.

项目摘要 这项提议的目标是寻求持续的支持，以增加和维持现有的酒精 研究资源，称为CoPARC(科罗拉多州肺-酒精研究合作)。CoPARC的 任务是促进研究，以防止酒精相关肺炎的发展，改善 其有害的并发症，并最终改善临床结果。酒精使用障碍(AUD)授予 社区获得性肺炎的风险增加了八倍。AUDS还会增加患有以下疾病的患者的发病率 肺炎，包括增加呼吸衰竭的风险，需要入住重症监护病房(ICU) 和机械通风。此外，由于病情的发展，与澳大利亚有关的肺炎往往会复杂化。 急性呼吸窘迫综合征(ARDS)。以科罗拉多大学丹佛分校(UCD)为中心 在医学博士Ellen L.Burnham的领导下，CoPARC基础设施已经实现了超过370名门诊患者的登记 有AUDS和无AUDS的受试者，以及237名肺炎或烧伤的危重患者，都建立了ARDS 在AUDS患者中更为普遍的危险因素。资源材料来自于机构 有NIAAA资助的酒精相关肺部疾病的翻译研究历史，包括UCD， 埃默里大学(欧盟)和洛约拉大学芝加哥分校(LUC)；加州大学旧金山分校 旧金山(加州大学旧金山分校)和NHLBI支持。目前，已收集了数千种生物标本，包括 支气管肺泡灌洗(BAL)液和细胞等量；支气管刷；和血液标本。到目前为止，26 来自11个外部机构的调查人员使用了92%的注册人员中的6100多个生物检验品 研究对象。对于更新，4个站点(欧盟、LUC、加州大学旧金山分校和内布拉斯加大学医学中心)和UCD 将为CoPARC收集材料。一个由UCD、欧盟、LUC、 路易斯安那州立大学、UNMC和托马斯·杰斐逊大学将为 CoPARC，包括确定生物杀虫剂分配的优先顺序，并确保促进使用 实现了资源共享。计划中的创新包括收集新的标本，如全肺 外植体；高通量基因组应用方面的专业知识；访问丰富的管理数据集 以及组织临床、库存和实验数据，以促进交叉- 调查员共享。更新的目标与NIAAA确定以下机制的战略计划一致 酒精行为和酒精相关病理，以更全面地了解酒精是如何对人类产生影响的 健康。它们包括：1)扩大从门诊获得的临床和生物材料并使之多样化 患有AUDS的受试者和危重患者，以及适当的对照，2)参与新兴的基于网络的 系统，以确定数据和生物量共享的优先顺序，并简化调查人员之间的通信 以及指导委员会，以及3)提高知名度和营销，以促进分销、增长和 资源的可持续性。